INTRODUCTION AND OBJECTIVES: Organ preserving therapy is emerging as an option for localized prostate cancer to minimize the morbidity associated with whole-gland therapy. We examine the short-term oncologic and functional data of the initial phase 1 trial of patients treated with focal transrectal MRI-guided focused ultrasound (MRgFUS) in North America.
METHODS: This phase 1 prospective study was approved by institutional review board. Eight patients with organ-confined PC visible on multiparametric MRI (mpMRI) and confirmed by the MRI-fusion biopsy (Artemis, Eigen) were enrolled. Patients were eligible with PSA 10ng/mL and Gleason score (GS) 7(4+3). Tumors larger than 1.5 cm in any dimension, too peripheral for a 5mm ablation margin or with concern for extraprostatic extension were excluded. Under MRI-guidance and real-time MR thermography, focal lesions were ablated using high frequency ultrasound energy delivered via an endorectal transducer with 990 elements (ExAblate 2100, InSightec). Incidence and severity of treatment-related adverse events were recorded at 6 months.
RESULTS: Eight patients with 10 peripheral zone lesions were treated. Prostate volume ranged from 25 to 50 cc with mean target volume of 2.7cc (range 0.4 -5.7cc). Mean procedure time was 248 minutes. Based on pre-treatment biopsy, six lesions were GS6(3+3), two were GS7(3+4) and two others were GS7(4+3). Treatments were all completed as planned without major technical delays or surgical complications. Mean post treatment non-perfused volume was 4.3cc (range 2.2 -7.6cc). Quality of life parameters were similar between baseline and 6-months in 6 of 8 patients. One patient with bilateral ablation had significantly worse storage symptoms while a second patient developed self-limiting acute prostatitis with erectile dysfunction. Mean PSA decreased from 5.06 to 3.4 ng/ml at 6 months. All patients were MRI negative in their treated regions. On biopsy, five patients were disease-free in treated regions (7 of 10 lesions). In one patient with a presumed GS7(4+3) tumor, a 2mm MRI-invisible focus of GS8(4+4) PC was seen in 1 of 5 cores from the ablation site. He underwent prostatectomy with negative surgical margins.
CONCLUSIONS: MRgFUS is a feasible and safe method of ablating localized PC. Further work is required to improve patient selection and address causes of failed ablation. Our study is limited by small sample size and brief follow-up. More meaningful oncologic and functional outcomes for MRgFUS can be assessed with larger trials with longer follow-up. METHODS: Among 3955 men who underwent primary whole gland prostate cryoablation, we identified 156 who had undergone prior therapy for BPH including transurethral needle ablation (n¼6), transurethral microwave thermotherapy (n¼11), and transurethral resection of the prostate (n ¼ 139). Patients with a history of medical or unspecified BPH therapy were excluded from the study. Primary outcomes included post-treatment urinary incontinence, urinary retention, erectile dysfunction (ED), and recto-urethral fistulae.
RESULTS: Median age was 71 years (IQR 66-76), median Gleason sum 6 (IQR6-7) and median PSA 6.6 ng/mL (IQR 4.8-9.8). Men who received prior BPH therapy were older with median age (74 vs 71, p<0.001), were more likely to have pretreatment Gleason sum !7 disease (50% vs 41.5%, p¼0.04) and have undergone neoadjuvant androgen deprivation therapy (50% vs.36%, p<0.001). In unadjusted analyses, prior interventional BPH therapy was associated with higher risks of post-operative urinary retention 22 of 149 (14.8%) vs. 325 of 3560 (9.1%), p¼0.02 and new-onset urinary incontinence 20 of 144(13.9%) vs. 251/3371 (7.5%), p¼0.005 compared to no prior therapy. Interventional BPH therapy was not correlated with the risk of development of recto-urethral fistula 2 of 149 (1.3%) vs. 46 of 3560 (1.3%), p¼0.9 or new onset ED 23 of 34 (67.7%) vs. 631 of 1195 (52.8%), p¼0.09 following surgery. On multivariable regression, prior interventional BPH therapy was associated with an 83% increased risk of urinary retention (OR 1.83, 95% CI 1.02-3.09, p¼0.03) and a 73% increased risk of newonset urinary incontinence (OR 1.73, 95% CI 1.03-2.78, p¼0.03) ( Table 1) . Vol. 197, No. 4S, Supplement, Monday, May 15, 2017 THE JOURNAL OF UROLOGY â e941 CONCLUSIONS: Prior interventional therapy for BPH is associated with increased risks of urinary retention and incontinence after whole gland prostate cryoablation. Nevertheless, in properly selected patients, prior bladder outlet procedures are not an absolute contraindication to cryotherapy. Consideration should be given to management protocol in those men including but not limited to time for catheter removal postoperatively and continuing BPH medical treatment
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MP70-18 PROSTATE RADIOFREQUENCY ABLATION FOCAL TREATMENT (PRORAFT): INTERIM RESULTS OF A PROSPECTIVE DEVELOPMENT STUDY
Clement Orczyk*, Chris Brew-graves, London, United Kingdom; Norman Williams, london, United Kingdom; Ingrid Potika, Navin Ramachandran, Alex Freeman, Mark Emberton, Hashim U Ahmed, London, United Kingdom INTRODUCTION AND OBJECTIVES: Radiofrequency ablation (RFA) using a bipolar coil design (EncageÔ device) which acts as a Faraday cage offer the versatility needed to perform focal treatment of localised prostate cancer whilst sparing critical anatomical and functional structures. We report preliminary outcomes of our ethics approved prospective development study investigating focal EncageÔ ablation (NCT02294903). Our primary objective was to determine the ablative efficacy 6 months after bipolar RFA. Secondary objectives included the assessment of genito-urinary toxicity.
METHODS: 21 men who had multi-parametric MR-visible index lesion concordant with transperineal biopsies and absence of clinically significant disease elsewhere with PSA </¼15ng/ml underwent daycase bipolar RFA with margins around the lesion of >/¼5mm using elastic image-fusion (SmartTargetÔ platform). mpMRI transperineal targeted biopsies of the ablated zone and any new suspicious areas were carried out at 6 months.
RESULTS: 20 men were treated,none were eligible for active surveillance. Data are available for 15 patients treated and followed up to 6 months. Patient characteristics are presented in Tab1. No significant residual disease was found in 13/15 patients. Two had clinically significant cancer of 6mm Gleason 7 (3+4) and 4mm Gleason 6, with one of these undergoing a retreatment. One harboured insignificant disease (1mm Gleason 6; pre-RFA 8 mm Gleason 7). Median PSA (IQR) at 6 months post RFA was 3.1 (1.2 to 4.8) ng/mL 2 patients showed decrease function in term of leakage (1 patient needed a urethral dilatation for stricture). For pad use, 3/15 patients started to use pad. IPSS changed from 9.2 to 8.9 and IPSS quality-of-life from 1.86 to 1.8. Across the 11 patients declaring in IIEF questionnaires some sexual stimulation, 2 patients with already poor erectile function had some decrease at the point to not be sufficient for penetrations. Erectile and bowel functions remained stable, as measured by the IIEF-15 and UCLA-EPIC bowel domain, respectively. EQ-5D and the FACT-P remained stable. There were 4 serious adverse events, none related to the procedure.
CONCLUSIONS: RFA using a bipolar device (EncageÔ) showed promising early disease control and a low profile of genitourinary toxicity. Trial completion to one-year follow-up is awaited and further phase II multicentre trials will be needed. METHODS: Prostate biopsies were collected from 10 very low risk prostate cancer patients (T1c, PSA density <0.15 ng / dL, Gleason 6, 2 cancer biopsy cores and 50% involvement any core with cancer) at diagnosis and 12 months after hemi-cryoablation. Cancer positive and negative lobes at diagnosis and the same areas 12 months after hemi-cryoablation (Diag+, Diag-, Cryo+ and Cryo-, respectively) were explored using immunohistochemistry for tumor infiltrating CD4+ T helper and CD8+ T cytotoxic cells (counted in 45 fields per patient with a 40x objective). The quantitative analysis of cells/mm 2 and CD8+/ CD4+ ratio were performed using ImageJ software.
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RESULTS: There was a significant increase in tumor infiltrating CD8+ T cytotoxic cells/mm 2 in post Cryo+ prostatic tissue (mean AE SD: 0.31 AE 0.30) compared to Diag+ (0.18 AE 0.15), p¼0.015. In contrast, tumor infiltrating CD4+ T helper cells/mm 2 showed a tendency to decrease in Cryo+ (0.26 AE 0.27) compared to Diag + (0.38 AE 0.52). Tumor infiltrating T cytotoxic / T helper cells ratio increased after hemicryoablation, with conceivable anti-tumor immunity and favorable prognosis.
CONCLUSIONS: This is the first study to show positive local immune modulation after prostate cancer cryoablation, characterized by increasing T cytotoxic / T helper cells ratio with potential to boost antitumor immune response. Long term follow-up and wider cohorts might e942 THE JOURNAL OF UROLOGY â Vol. 197, No. 4S, Supplement, Monday, May 15, 2017 
